Roche Forges Ahead With Taspoglutide Despite Cancer Signal With Competitor GLP-1
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche expects Phase III data on the type 2 diabetes drug to be available by the end of the year and maintains that any carcinogenicity issue is rodent-specific.
You may also be interested in...
Victoza Clears European Regulators Without Thyroid Cancer Restrictions
NovoNordisk is facing a much easier path for Victoza (liraglutide) in Europe than the rocky road the type 2 diabetes therapy is on in the U.S
Victoza Clears European Regulators Without Thyroid Cancer Restrictions
NovoNordisk is facing a much easier path for Victoza (liraglutide) in Europe than the rocky road the type 2 diabetes therapy is on in the U.S
Lilly Provides Regulatory Update On Two Key Drugs: Zyprexa LAI, Byetta LAR
Firm responds to FDA’s “complete response” letter for the long-acting atypical antipsychotic and anticipates a six-month review.